A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3

NCT00000844 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

560

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Interferon alfa-n3
DRUG: Interferon alfa-n1

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)